Clinical Cancer Research: A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children’s Oncology Group Phase I and Pilot Consortium (ADVL0921)

June 1, 2019

Yael P Mossé 1 2, Elizabeth Fox 3 2, David T Teachey 3 2, Joel M Reid 4, Stephanie L Safgren 4, Hernan Carol 5, Richard B Lock 5, Peter J Houghton 6, Malcolm A Smith 7, David Hall 8, Donald A Barkauskas 8, Mark Krailo 9, Stephan D Voss 10, Stacey L Berg 11, Susan M Blaney 11, Brenda J Weigel 10 Abstract Purpose: Aurora A kinase (AAK) plays an integral role in the mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a […]

Clinical Cancer Research: Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

April 25, 2019

Caitlin D Lowery 1, Michele Dowless 1, Matthew Renschler 1, Wayne Blosser 1, Alle B VanWye 1, Jennifer R Stephens 1, Philip W Iversen 1, Aimee Bence Lin 1, Richard P Beckmann 1, Kateryna Krytska 2, Kristina A Cole 2, John M Maris 2, Douglas S Hawkins 3, Brian P Rubin 4, Raushan T Kurmasheva 5, Peter J Houghton 5, Richard Gorlick 6, E Anders Kolb 7, Min H Kang 8, C Patrick Reynolds 8, Stephen W Erickson 9, Beverly A Teicher 10, Malcolm A Smith 10, Louis F Stancato 11 Abstract Purpose: Checkpoint kinase 1 (CHK1) inhibitors potentiate the DNA-damaging effects of […]

Pediatric Blood & Cancer: Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts

April 23, 2019

Luke Jones, Hannah McCalmont, Kathryn Evans, Chelsea Mayoh, Raushan T. Kurmasheva, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith,  Richard B. Lock Abstract Background Denintuzumab mafodotin (SGN‐CD19A) is a CD19‐targeting antibody‐drug conjugate, comprising a monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin F. Since denintuzumab mafodotin has previously shown activity against B‐cell malignancies in early‐stage clinical trials, it […]

YouTube: Experimental Biology TV, WebsEdgeMedicine

April 4, 2019

“Cancers in children are rare, and the genetics and epigenetic causes are very different from those of adults. Consequently, the study of the etiology and potential therapies for these tumors requires intensive research. The majority of children diagnosed with cancer survive their disease, but the long-term consequences of current treatments lead to lifelong health issues. […]

Clinical Cancer Research: Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling

December 1, 2018

Michele Dowless, Caitlin D. Lowery, Terry Shackleford, Matthew Renschler, Jennifer Stephens, Robert Flack, Wayne Blosser, Simone Gupta, Julie Stewart, Yue Webster, Jack Dempsey, Alle B. VanWye, Philip Ebert, Philip Iversen, Jonathan B. Olsen, Xueqian Gong, Sean Buchanan, Peter Houghton, and Louis Stancato Abstract Purpose: Ewing sarcoma (ES) is a rare and highly malignant cancer that occurs in the bone and surrounding tissue of children and adolescents. The EWS/ETS fusion transcription factor that drives ES pathobiology was previously demonstrated to modulate cyclin D1 expression. In this study, we evaluated abemaciclib, a small-molecule CDK4, and CDK6 (CDK4 […]

Nature Communications: MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma

October 31, 2018

Nourhan Abdelfattah, Subapriya Rajamanickam, Subbarayalu Panneerdoss, Santosh Timilsina, Pooja Yadav, Benjamin C. Onyeagucha, Michael Garcia, Ratna Vadlamudi, Yidong Chen, Andrew Brenner, Peter Houghton & Manjeet K. Rao Abstract Despite improvements in overall survival, only a modest percentage of patients survive high-risk medulloblastoma. The devastating side effects of radiation and chemotherapy substantially reduce the quality of life for surviving patients. Here, using genomic screens, we identified miR-584-5p as a […]

Science Advances: Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression

October 3, 2018

Subbarayalu Panneerdoss1,2,*, Vijay K. Eedunuri1,2,*, Pooja Yadav1,2, Santosh Timilsina1,2, Subapriya Rajamanickam2,3, Suryavathi Viswanadhapalli4, View ORCID ProfileNourhan Abdelfattah1,2, Benjamin C. Onyeagucha1,2, View ORCID ProfileXiadong Cui5, Zhao Lai2, View ORCID ProfileTabrez A. Mohammad2, View ORCID ProfileYogesh K. Gupta2,6, Tim Hui-Ming uang3, Yufei Huang5,†, View ORCID ProfileYidong Chen2,7,† and View ORCID ProfileManjeet K. Rao1,2,† Abstract The importance of RNA methylation in biological processes is an emerging focus of the investigation. We report that altering […]

JCI Insight: IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis

August 23, 2018

Amy C. Gross,1 Hakan Cam,1,2 Doris A. Phelps,3 Amanda J. Saraf,2,4 Hemant K. Bid,1,2 Maren Cam,1 Cheryl A. London,5,6 Sarah A. Winget,1 Michael A. Arnold,7,8 Laura Brandolini,9 Xiaokui Mo,10 John M. Hinckley,1,11 Peter J. Houghton,3 and Ryan D. Roberts1,2,4 Abstract: Osteosarcoma (OS), a malignant tumor of bone, kills through aggressive metastatic spread almost exclusively to the lung. Mechanisms driving this tropism for lung tissue remain unknown, though likely invoke […]

Fraternal Order of Eagles: People Helping People

May 18, 2018

2016-17 Texas State Presidents Ron Poling and Rachel Graham were proud to present a check for $50,000 to Dr. Houghton, Director of the Greehey Children’s Cancer Research Institute at the University of Texas Health Science Center in San Antonio. Ron and Rachel would like to thank all the Texas State Aerie and Auxiliary members for […]